Medication
Definition
This
page
is
part
of
the
FHIR
Specification
(v4.3.0:
R4B
(v5.0.0-ballot:
R5
Ballot
-
STU
see
ballot
notes
).
The
current
version
which
supercedes
this
version
is
5.0.0
.
For
a
full
list
of
available
versions,
see
the
Directory
of
published
versions
.
Page
versions:
R5
R4B
| Biomedical Research and Regulation Work Group | Maturity Level : N/A | Standards Status : Informative | Compartments : Not linked to any defined compartments |
Raw Turtle (+ also see Turtle/RDF Format Specification )
Basic details of a product, only using MedicinalProductDefinition and no other resources
@prefix fhir: <http://hl7.org/fhir/> . @prefix owl: <http://www.w3.org/2002/07/owl#> . @prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> . @prefix xsd: <http://www.w3.org/2001/XMLSchema#> . # - resource -------------------------------------------------------------------<http://hl7.org/fhir/MedicinalProductDefinition/equilidem-basics> a fhir:MedicinalProductDefinition;[a fhir:MedicinalProductDefinition; fhir:nodeRole fhir:treeRoot; fhir:Resource.id [ fhir:value "equilidem-basics"]; fhir:DomainResource.text [ fhir:Narrative.status [ fhir:value "generated" ]; fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n <p>\n <b>\n Generated Narrative\n </b>\n </p>\n <p>\n <b>\n Id\n </b>\n : equilidem-basics\n </p>\n <p>\n <b>\n Identifier\n </b>\n : Equilidem25\n </p>\n <p>\n <b>\n Combined Pharmaceutical Dose Form\n </b>\n :\n <span title=\"Codes: {http://example.org.uk/fhir/dosefom tablet}\">\n tablet\n </span>\n </p>\n <p>\n <b>\n Indication\n </b>\n : Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class >= II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.\n </p>\n <p>\n <b>\n Legal Status Of Supply\n </b>\n :\n <span title=\"Codes: {http://example.org.uk/fhir/legalstatusofsupply POM}\">\n Prescription only medicine\n </span>\n </p>\n <p>\n <b>\n Classification\n </b>\n :\n <span title=\"Codes: {http://www.whocc.no/atc/example B01A}\">\n ATC: B01A\n </span>\n </p>\n <p>\n <b>\n Ingredient\n </b>\n :\n </p>\n <ul>\n <li>\n <span>\n Equilidonium Phosphate\n </span>\n </li>\n <li>\n <span>\n Calcium Carbonate\n </span>\n </li>\n </ul>\n <h3>\n Names\n </h3>\n <table class=\"grid\">\n <tr>\n <td>\n -\n </td>\n <td>\n <b>\n Product Name\n </b>\n </td>\n </tr>\n <tr>\n <td>\n *\n </td>\n <td>\n Equilidem 2.5 mg film-coated tablets\n </td>\n </tr>\n </table>\n <h3>\n Cross References\n </h3>\n <table class=\"grid\">\n <tr>\n <td>\n -\n </td>\n <td>\n <b>\n Product\n </b>\n </td>\n </tr>\n <tr>\n <td>\n *\n </td>\n <td>\n Link to generic equivalent\n </td>\n </tr>\n </table>\n <h3>\n Manufacturing/Business Operations\n </h3>\n <table class=\"grid\">\n <tr>\n <td>\n -\n </td>\n <td>\n <b>\n Manufacturer\n </b>\n </td>\n </tr>\n <tr>\n <td>\n *\n </td>\n <td>\n <span>\n EquiliDrugCo Inc.\n </span>\n </td>\n </tr>\n </table>\n </div>" ]; fhir:MedicinalProductDefinition.identifier [ fhir:index 0; fhir:Identifier.system [ fhir:value "http://example.org.uk/fhir/product" ]; fhir:Identifier.value [ fhir:value "Equilidem25" ] ]; fhir:MedicinalProductDefinition.combinedPharmaceuticalDoseForm [ fhir:CodeableConcept.coding [ fhir:index 0; fhir:Coding.system [ fhir:value "http://example.org.uk/fhir/dosefom" ]; fhir:Coding.code [ fhir:value "tablet" ] ] ]; fhir:MedicinalProductDefinition.indication [ fhir:value "Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class >= II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults."]; fhir:MedicinalProductDefinition.legalStatusOfSupply [ fhir:CodeableConcept.coding [ fhir:index 0; fhir:Coding.system [ fhir:value "http://example.org.uk/fhir/legalstatusofsupply" ]; fhir:Coding.code [ fhir:value "POM" ]; fhir:Coding.display [ fhir:value "Prescription only medicine" ] ] ]; fhir:MedicinalProductDefinition.classification [ fhir:index 0; fhir:CodeableConcept.coding [ fhir:index 0; fhir:Coding.system [ fhir:value "http://www.whocc.no/atc/example" ]; fhir:Coding.code [ fhir:value "B01A" ] ] ]; fhir:MedicinalProductDefinition.ingredient [ fhir:index 0; fhir:CodeableConcept.text [ fhir:value "Equilidonium Phosphate" ] ], [ fhir:index 1; fhir:CodeableConcept.text [ fhir:value "Calcium Carbonate" ] ]; fhir:MedicinalProductDefinition.name [ fhir:index 0; fhir:MedicinalProductDefinition.name.productName [ fhir:value "Equilidem 2.5 mg film-coated tablets" ] ]; fhir:MedicinalProductDefinition.crossReference [ fhir:index 0; fhir:MedicinalProductDefinition.crossReference.product [ fhir:CodeableReference.reference [fhir:link <http://hl7.org/fhir/MedicinalProductDefinition/genericEquilidonium>;fhir:Reference.reference [ fhir:value "MedicinalProductDefinition/genericEquilidonium" ] ] ] ]; fhir:MedicinalProductDefinition.operation [ fhir:index 0; fhir:MedicinalProductDefinition.operation.organization [ fhir:index 0; fhir:Reference.display [ fhir:value "EquiliDrugCo Inc." ] ]] . <http://hl7.org/fhir/MedicinalProductDefinition/genericEquilidonium> a fhir:MedicinalProductDefinition .]] . # - ontology header ------------------------------------------------------------<http://hl7.org/fhir/MedicinalProductDefinition/equilidem-basics.ttl> a owl:Ontology; owl:imports fhir:fhir.ttl; owl:versionIRI <http://build.fhir.org/MedicinalProductDefinition/equilidem-basics.ttl> .[a owl:Ontology; owl:imports fhir:fhir.ttl] . # -------------------------------------------------------------------------------------
Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.
FHIR
®©
HL7.org
2011+.
FHIR
Release
4B
(v4.3.0)
hl7.fhir.r4b.core#4.3.0
R5
Ballot
hl7.fhir.core#5.0.0-ballot
generated
on
Sat,
May
28,
Sep
10,
2022
12:56+1000.
05:05+1000.
Links:
Search
|
Version
History
|
Table
of
Contents
|
Glossary
|
QA
Page
|
Compare
to
R4
R4B
|
Compare
to
R5
Draft
|
|
Propose
a
change